Special emphasis on bone health management in prostate cancer patients: a prospective longitudinal study
ABSTRACT Introduction: Use of androgen deprivation therapy (ADT) in carcinoma prostate (CaP) has deleterious effect on bone mineral density (BMD) leading to increase incidence of osteoporosis and skeletal-related events. We evaluated bone health status and impact of bone-directed therapy (BDT) and ADT on BMD in these patients from Jan 2015-Dec 2018. Materials and Method: Baseline bone health was assessed using Tc-99 MDP Bone scan/ DEXA scan for patients on ADT. Monthly zoledronic acid (ZA) was given to high-risk candidates (T-score ≤ 2.5 or previous hip/vertebral fracture) or Skel et al. metastatic patients who were receiving ADT. Baseline and follow-up (at 12-months) BMD using DEXA scan at various sites (spine, femur total, femur neck and radius) and subjective improvement in bony pain using Numeric Pain Rating Score after administration of ZA were compared. Results: A total of 96-patients of locally advanced and metastatic prostate cancer receiving ADT with or without BDT were included in the study cohort. Mean age of presentation was 68.4 ±15.61 years. Median serum PSA was 32.2±13.1ng/mL. There was significant improvement in mean BMD (T-score) in 64-patients post ZA therapy at 12-months (at femoral total, femoral neck and spine; 0.95, 0.79 and 0.68, respectively) (p
Publication date: Available online 30 May 2020Source: Nanomedicine: Nanotechnology, Biology and MedicineAuthor(s): Renjie Wang, Zhengwei Cao, Lan Wei, Lin Bai, Hui Wang, Shiyi Zhou, Shuyue Zhan, Bin Ji, Zibo Li, Shi Gao, Jin Xie, Qingjie Ma
Publication date: Available online 30 May 2020Source: Materials Science and Engineering: AAuthor(s): Chengcheng Zhang, Kai Feng, Hiroyuki Kokawa, Bolun Han, Zhuguo Li
Publication date: Available online 30 May 2020Source: Neuroscience &Biobehavioral ReviewsAuthor(s): Léa J. Becker, Sarah H. Journée, Pierre-Eric Lutz, Ipek Yalcin
(American Association for Cancer Research) Among patients with both colorectal cancer and diabetes in Korea, those who had a high adherence to their oral diabetes medication had a significantly reduced risk of overall mortality compared with those with lower adherence.
Publication date: Available online 30 May 2020Source: Sensors and Actuators A: PhysicalAuthor(s): Xiaoyu Duan, Shuangliang Li, Anthony Medellin, Chao Ma, Jun Zou
Publication date: Available online 30 May 2020Source: Biochimica et Biophysica Acta (BBA) - Molecular Cell ResearchAuthor(s): Deborah Delbue, Bruna S. Mendonça, Marcela C. Robaina, Lauana G.T. Lemos, Pedro I. Lucena, João P.B. Viola, Lídia M. Magalhães, Susanne Crocamo, Caio A.B. Oliveira, Felipe R. Teixeira, Raquel C. Maia, Gabriela Nestal de Moraes
Publication date: Available online 30 May 2020Source: Life SciencesAuthor(s): Lijia Mai, Xiao Zhu, Fang Huang, Hongwen He, Wenguo Fan
Publication date: Available online 30 May 2020Source: Carbohydrate PolymersAuthor(s): Luana Heimfarth, Klécia Santos dos Anjos, Yasmim Maria Barbosa Gomes de Carvalho, Bruno Lucena dos Santos, Mairim Russo Serafini, Antônio Guilherme de Carvalho Neto, Paula Santos Nunes, José Ivo Araújo Beserra Filho, Sara Pereira da Silva, Alessandra Mussi Ribeiro, Daniel Pereira Bezerra, Ricardo Neves Marreto, Jullyana de Souza Siqueira Quintans, Adriano Antunes de Souza Araújo, Henrique Douglas Melo Coutinho, Marcus T. Scotti, Luciana Scotti, Lucindo José Quintans-Júnior
Publication date: Available online 30 May 2020Source: Sensors and Actuators B: ChemicalAuthor(s): Abdelilah Asserghine, Martina Medvidović-Kosanović, Livia Nagy, Ricardo M. Souto, Geza Nagy
Authors: Doria C, Leali PT, Solla F, Maestretti G, Balsano M, Scarpa RM Abstract INTRODUCTION: Osteoporosis is a complication of androgen deprivation therapy (ADT) in men with prostate carcinoma. The best defense against osteoporosis in prostate cancer is to identify patients with a high risk for fracture during the first clinical visit, select an effective anti-osteoporosis agent, and advise the patient to change his lifestyle and diet to prevent further bone loss. New agents include denosumab, a human monoclonal antibody that inhibits the RANK ligand (RANKL). RANKL promotes the formation, activity, and survival o...